AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6688500 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone sodium phosphate (0.6 mg/kg)
Number of subjects: 72
Study 6688500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 30514113 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy
Number of subjects: 60
Study 30514113 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES application
Number of subjects: 60
Study 30253035 — intervention group
Group type: EXPERIMENTAL
Intervention: Alt‐RAMEC/FM
Number of subjects: 34
Study 30253035 — intervention group
Group type: COMPARATOR
Intervention: RME/FM
Number of subjects: 34
Study 30351691 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled halotherapy (10 procedures with sodium chloride dry aerosol)
Number of subjects: 73
Study 30351691 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical therapy
Number of subjects: 73
Study 23947690 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Arnica
Number of subjects: 20
Study 23947690 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 20
Study 22918608 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural view presentation with minimum delay
Number of subjects: 0
Study 22918608 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural view presentation with delay (33 to 150 ms)
Number of subjects: 0
Study 22918608 — intervention group
Group type: COMPARATOR
Intervention: Mirror-reversed and/or inverted views
Number of subjects: 0
Study 22918608 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrete movements
Number of subjects: 0
Study 22918608 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous movements
Number of subjects: 0
Study 22918608 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant hand movements
Number of subjects: 0
Study 22918608 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dominant hand movements
Number of subjects: 0
Study 21225519 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training with biofeedback function
Number of subjects: 0
Study 21225519 — intervention group
Group type: COMPARATOR
Intervention: Control group (rehabilitation regime without treadmill exercises)
Number of subjects: 0
Study 17332278 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib for GIST
Number of subjects: 0
Study 17332278 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib for advanced renal cell carcinoma
Number of subjects: 0
Study 15377314 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 U botulinum toxin A in the frontal muscles and placebo in the neck muscles
Number of subjects: 60
Study 15377314 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 U botulinum toxin A in the frontal and neck muscles
Number of subjects: 60
Study 15377314 — intervention group
Group type: COMPARATOR
Intervention: Placebo in the frontal and neck muscles
Number of subjects: 60
Study 15377314 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 U botulinum toxin A
Number of subjects: 60
Study 15377314 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 U botulinum toxin A
Number of subjects: 60
Study 11196518 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually attended treatment
Number of subjects: 126
Study 11196518 — intervention group
Group type: EXPERIMENTAL
Intervention: Small group format program
Number of subjects: 126
Study 11196518 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 126
Study 9643397 — intervention group
Group type: EXPERIMENTAL
Intervention: Inborn status (delivery in a tertiary care facility)
Number of subjects: 202
Study 9643397 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple pregnancies
Number of subjects: 202
Study 9643397 — intervention group
Group type: COMPARATOR
Intervention: Presence of a hospital staff paediatrician in the delivery room
Number of subjects: 202
Study 7977319 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO (50 U/kg subcutaneously three times weekly)
Number of subjects: 83
Study 7977319 — intervention group
Group type: COMPARATOR
Intervention: Untreated (control group)
Number of subjects: 83
Study 7977319 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO (treatment group)
Number of subjects: 83
Study 2493536 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 0
Study 2493536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30700564 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Infusion of Vancomycin (CIV)
Number of subjects: 104
Study 30700564 — intervention group
Group type: COMPARATOR
Intervention: Intermittent Infusion of Vancomycin (IIV)
Number of subjects: 104
Study 28437506 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal Femur Nail (PFN)
Number of subjects: 48
Study 28437506 — intervention group
Group type: COMPARATOR
Intervention: Proximal Femur Locking Compression Plate (PFLCP)
Number of subjects: 48
Study 25556080 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (n = 49)
Number of subjects: 99
Study 25556080 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine (n = 15)
Number of subjects: 99
Study 25556080 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (n = 19)
Number of subjects: 99
Study 25556080 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (n = 16)
Number of subjects: 99
Study 23099220 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium nitrate supplementation
Number of subjects: 0
Study 23099220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21773588 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicory inulin (20 g day(-1))
Number of subjects: 12
Study 19845240 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg
Number of subjects: 80
Study 19845240 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam 0.5 mg
Number of subjects: 80
Study 16123923 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound examination by examiner A
Number of subjects: 239
Study 16123923 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound examination by examiner B
Number of subjects: 239
Study 16123923 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound examination by both examiners
Number of subjects: 239
Study 10355845 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat emulsion (30% of total calories) administered from day of operation to POD 7
Number of subjects: 17
Study 10355845 — intervention group
Group type: COMPARATOR
Intervention: Glucose as a non-protein calorie source administered from day of operation to POD 7
Number of subjects: 17
Study 7491136 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole and erythromycin
Number of subjects: 624
Study 7491136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study 2031364 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 133
Study 2031364 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl sulfoxide
Number of subjects: 133
Study 2031364 — intervention group
Group type: COMPARATOR
Intervention: Graduated compression bandages (control)
Number of subjects: 133
Study 7213520 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin (3 mg/70 kg)
Number of subjects: 7
Study 7213520 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin (6 mg/70 kg)
Number of subjects: 7
Study 7213520 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin (12 mg/70 kg)
Number of subjects: 7
Study 7213520 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin (3, 6, 12 mg/70 kg)
Number of subjects: 7
Study 7213520 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (10 mg/70 kg)
Number of subjects: 7
Study 7213520 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (20 mg/70 kg)
Number of subjects: 7
Study 7213520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31743394 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 103
Study 31022102 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco communication evidence-based practice implementation
Number of subjects: 0
Study 31022102 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco policy and program implementation
Number of subjects: 0
Study 30278495 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mL of 0.375% ropivacaine mixed with 1 μg/kg dexmedetomidine (group D)
Number of subjects: 60
Study 30278495 — intervention group
Group type: COMPARATOR
Intervention: 40 mL of 0.375% ropivacaine (group C)
Number of subjects: 60
Study 26499503 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care provided by a certified diabetes-educator pharmacist
Number of subjects: 100
Study 26499503 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 100
Study 26499503 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care
Number of subjects: 100
Study 25172514 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Management of Neonatal and Childhood Illness intervention
Number of subjects: 60480
Study 22126894 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (ER)
Number of subjects: 33
Study 22126894 — intervention group
Group type: COMPARATOR
Intervention: Propofol (PR)
Number of subjects: 33
Study 20616786 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-pharmacist intervention group
Number of subjects: 132
Study 20616786 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 132
Study 17289888 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA3 urine test
Number of subjects: 583
Study 17289888 — intervention group
Group type: COMPARATOR
Intervention: Serum PSA
Number of subjects: 583
Study 15781340 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell collection (PBSCC) and autologous stem cell transplantation (ASCT)
Number of subjects: 14
Study 12815800 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy with at least three drugs
Number of subjects: 75
Study 9813401 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (up to 2,400 mg/day)
Number of subjects: 18
Study 7712303 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g sorbitol and 20 g glucose
Number of subjects: 14
Study 7712303 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g sorbitol and 9 g lipids
Number of subjects: 14
Study 7712303 — intervention group
Group type: COMPARATOR
Intervention: 20 g sorbitol alone
Number of subjects: 14
Study 2540650 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (5 mg twice daily)
Number of subjects: 10
Study 2540650 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (2.5 mg twice daily)
Number of subjects: 10
Study 2540650 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 10
Study 30528828 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 40 mg twice daily (APR40)
Number of subjects: 185
Study 30528828 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice daily (APR30)
Number of subjects: 185
Study 30528828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 28174196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac CT
Number of subjects: 350
Study 28174196 — intervention group
Group type: COMPARATOR
Intervention: Functional testing
Number of subjects: 350
Study 25263246 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic computer assisted surgical technique
Number of subjects: 200
Study 25263246 — intervention group
Group type: COMPARATOR
Intervention: Conventional instrumentation
Number of subjects: 200
Study 23591293 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise (HIIE)
Number of subjects: 18
Study 23591293 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric moderate-intensity continuous exercise (MICE)
Number of subjects: 18
Study 23591293 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 18
Study 21372124 — intervention group
Group type: EXPERIMENTAL
Intervention: Sagopilone 16 mg/m² as a 3-h i.v. infusion every 21 days for up to 6 weeks
Number of subjects: 63
Study 21372124 — intervention group
Group type: EXPERIMENTAL
Intervention: Sagopilone 16 mg/m² as a 0.5-h i.v. infusion every 21 days for up to 6 weeks
Number of subjects: 63
Study 21372124 — intervention group
Group type: EXPERIMENTAL
Intervention: Sagopilone (both infusion schedules)
Number of subjects: 63
Study 19998333 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagining group (IG) - used a computer-imaging program (HAAIR) to simulate baldness and wig use
Number of subjects: 45
Study 19998333 — intervention group
Group type: COMPARATOR
Intervention: Standardized Care group (SCG) - directed to a resource room for women with chemotherapy-related alopecia
Number of subjects: 45
Study 17125995 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid preload before spinal anesthesia
Number of subjects: 200
Study 17125995 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid preload before spinal anesthesia
Number of subjects: 200
Study 17125995 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid preload before combined spinal-epidural anesthesia
Number of subjects: 200
Study 17125995 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid preload before combined spinal-epidural anesthesia
Number of subjects: 200
Study 16393218 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of ketorolac trometamol (KT) administered intravenously as premedication 30 min prior to procedure
Number of subjects: 140
Study 16393218 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline) administered intravenously as premedication 30 min prior to procedure
Number of subjects: 140
Study 11925518 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (400% above the seizure threshold) right unilateral (RUL) ECT
Number of subjects: 24
Study 11925518 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose (150% above seizure threshold) RUL ECT
Number of subjects: 24
Study 11925518 — intervention group
Group type: COMPARATOR
Intervention: Low dose (just above seizure threshold) bifrontal (BF) ECT
Number of subjects: 24
Study 9464674 — intervention group
Group type: EXPERIMENTAL
Intervention: In-house referral by general practitioners to a colleague in the practice for review of hospital care need
Number of subjects: 8
Study 7647379 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile flow during cardiopulmonary bypass
Number of subjects: 2
Study 7647379 — intervention group
Group type: COMPARATOR
Intervention: Continuous flow during cardiopulmonary bypass
Number of subjects: 2
Study 2667310 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil (25 or 50 mg)
Number of subjects: 10
Study 2667310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 55890 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 24
Study 55890 — intervention group
Group type: COMPARATOR
Intervention: Methimazole 40 mg per day
Number of subjects: 24
Study 31011912 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex Positive! video-based web intervention
Number of subjects: 830
Study 31011912 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 830
Study 28244906 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly teriparatide administration for 6 months postoperatively
Number of subjects: 75
Study 28244906 — intervention group
Group type: COMPARATOR
Intervention: No teriparatide (control arm)
Number of subjects: 75
Study 28244906 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly teriparatide administration
Number of subjects: 75
Study 25304755 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated dose 4+8+4mg betamethasone
Number of subjects: 37
Study 25304755 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose 16mg betamethasone
Number of subjects: 37
Study 25304755 — intervention group
Group type: COMPARATOR
Intervention: Control (no betamethasone)
Number of subjects: 37
Study 25304755 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (both doses)
Number of subjects: 37
Study 23510092 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined HBO2/NBH (60 minutes of HBO2 at 1.5 ATA followed by 3 hours of NBH at 100% FiO2 at 1.0 ATA)
Number of subjects: 42
Study 23510092 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined HBO2/NBH
Number of subjects: 42
Study 21223344 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 400 mg every 2 weeks (q2w)
Number of subjects: 0
Study 21223344 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 400 mg every 4 weeks (q4w)
Number of subjects: 0
Study 19947366 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (including mastectomy, neoadjuvant and adjuvant chemohormonal and radiotherapy)
Number of subjects: 444
Study 19947366 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 444
Study 17854247 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of zonisamide and bupropion
Number of subjects: 18
Study 17854247 — intervention group
Group type: COMPARATOR
Intervention: Zonisamide alone
Number of subjects: 18
Study 15167990 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT (Tension-free Vaginal Tape)
Number of subjects: 200
Study 15167990 — intervention group
Group type: COMPARATOR
Intervention: Colposuspension
Number of subjects: 200
Study 11304902 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron 1 mg p.o. bid
Number of subjects: 12
Study 11304902 — intervention group
Group type: COMPARATOR
Intervention: No alosetron
Number of subjects: 12
Study 9219782 — intervention group
Group type: EXPERIMENTAL
Intervention: Stonetome combination catheter
Number of subjects: 17
Study 9219782 — intervention group
Group type: COMPARATOR
Intervention: Conventional sphincterotomy with separate balloon sweep
Number of subjects: 17
Study 7902021 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort 30 mg/d
Number of subjects: 24
Study 7902021 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort 60 mg/d
Number of subjects: 24
Study 7902021 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort 6 mg/d
Number of subjects: 24
Study 7902021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3650597 — intervention group
Group type: COMPARATOR
Intervention: Questionnaire only
Number of subjects: 191
Study 3650597 — intervention group
Group type: EXPERIMENTAL
Intervention: Bogus-pipeline only
Number of subjects: 191
Study 3650597 — intervention group
Group type: EXPERIMENTAL
Intervention: Bogus-pipeline with saliva collection
Number of subjects: 191
Study 29851569 — intervention group
Group type: EXPERIMENTAL
Intervention: NAP (afternoon nap approximately 90 minutes before evening exercise)
Number of subjects: 11
Study 29851569 — intervention group
Group type: COMPARATOR
Intervention: CON (no afternoon nap)
Number of subjects: 11
Study 29851569 — intervention group
Group type: EXPERIMENTAL
Intervention: NAP
Number of subjects: 11
Study 27256922 — intervention group
Group type: EXPERIMENTAL
Intervention: MK‐1064 (OX2R antagonist)
Number of subjects: 0
Study 27256922 — intervention group
Group type: COMPARATOR
Intervention: Dual orexin receptor antagonists (for comparison)
Number of subjects: 0
Study 25614171 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month prednisolone treatment (0.5 mg·kg(‐1)·day(‐1) for 3 months, then tapered)
Number of subjects: 44
Study 25614171 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month prednisolone treatment (0.5 mg·kg(‐1)·day(‐1) for 6 months, then tapered)
Number of subjects: 44
Study 25614171 — intervention group
Group type: COMPARATOR
Intervention: Both treatment groups (3-month and 6-month prednisolone)
Number of subjects: 44
Study 23165467 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide (ENF) for 24 weeks
Number of subjects: 195
Study 23165467 — intervention group
Group type: COMPARATOR
Intervention: Control (no enfuvirtide)
Number of subjects: 195
Study 20595110 — intervention group
Group type: EXPERIMENTAL
Intervention: CPCS stem
Number of subjects: 34
Study 20595110 — intervention group
Group type: COMPARATOR
Intervention: Exeter stem
Number of subjects: 34
Study 19056708 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer antiretroviral therapies
Number of subjects: 0
Study 19056708 — intervention group
Group type: COMPARATOR
Intervention: Earlier antiretroviral therapies
Number of subjects: 0
Study 16630150 — intervention group
Group type: EXPERIMENTAL
Intervention: RWJ-58643 (100 microg)
Number of subjects: 16
Study 16630150 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (200 microg)
Number of subjects: 16
Study 16630150 — intervention group
Group type: EXPERIMENTAL
Intervention: RWJ-58643 (300 microg)
Number of subjects: 16
Study 16630150 — intervention group
Group type: EXPERIMENTAL
Intervention: RWJ-58643 (600 microg)
Number of subjects: 16
Study 16630150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12751980 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programmes for bartenders (n = 40) in intervention pubs
Number of subjects: 1322
Study 12751980 — intervention group
Group type: COMPARATOR
Intervention: Control pubs (no educational programme)
Number of subjects: 1322
Study 10769553 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream (1 g)
Number of subjects: 153
Study 10769553 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream (1 g)
Number of subjects: 153
Study 10769553 — intervention group
Group type: COMPARATOR
Intervention: Mepivacaine infiltration (0.2 ml of 1%)
Number of subjects: 153
Study 9314631 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro in combination with sulfonylureas
Number of subjects: 25
Study 9314631 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylureas alone
Number of subjects: 25
Study 8349803 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass pollen immunotherapy
Number of subjects: 40
Study 8349803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3713148 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel automated visual field testing instrument
Number of subjects: 0
Study 3713148 — intervention group
Group type: COMPARATOR
Intervention: Conventional automatic tests
Number of subjects: 0
Study 29858713 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPASS intervention
Number of subjects: 0
Study 27543252 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 60